Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Gandhi S, Slomba RT, Janes C, Fitzpatrick V, Miller J, Attwood K, Ioannou G, Ozbey S, De Souza I, Roudko V, Kumar P, Kalathil S, Kokolus KM, Wang J, Cortes Gomez E, Takabe K, Edge S, Young J, Cappuccino H, Opyrchal M, O'Connor T, Levine EG, Gnjatic S, Kalinski P. Gandhi S, et al. Among authors: kalinski p. J Immunother Cancer. 2024 Nov 14;12(11):e010058. doi: 10.1136/jitc-2024-010058. J Immunother Cancer. 2024. PMID: 39542655 Free PMC article. Clinical Trial.
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Sarma M, et al. Among authors: kalinski p. Breast Cancer Res Treat. 2022 Apr;192(2):411-421. doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 9. Breast Cancer Res Treat. 2022. PMID: 35000093 Free PMC article.
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Gandhi S, et al. Among authors: kalinski p. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. J Immunother Cancer. 2023. PMID: 37963636 Free PMC article.
Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M, Kawaguchi T, Yan L, Peng X, Qi Q, Tian W, Schulze A, McDonald KA, Narayanan S, Young J, Liu S, Morris LG, Chan TA, Kalinski P, Matsuyama R, Otsuji E, Endo I, Takabe K. Oshi M, et al. Among authors: kalinski p. Am J Cancer Res. 2021 Jul 15;11(7):3628-3644. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354864 Free PMC article.
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Fountzilas C, et al. Among authors: kalinski p. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. Clin Cancer Res. 2021. PMID: 34645646 Free PMC article. Clinical Trial.
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1.
Taylor JL, Kokolus KM, Basse PH, Filderman JN, Cosgrove CE, Watkins SC, Gambotto A, Lowe DB, Edwards RP, Kalinski P, Storkus WJ. Taylor JL, et al. Among authors: kalinski p. Vaccines (Basel). 2024 Jul 15;12(7):777. doi: 10.3390/vaccines12070777. Vaccines (Basel). 2024. PMID: 39066414 Free PMC article.
165 results